Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Mar 31, 2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.
Read more at globenewswire.com
